Lodestar Private Asset Management LLC Cuts Stake in Eli Lilly and Company $LLY

Lodestar Private Asset Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 764 shares of the company’s stock after selling 48 shares during the quarter. Lodestar Private Asset Management LLC’s holdings in Eli Lilly and Company were worth $595,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in LLY. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $833.08 on Friday. The firm has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a PEG ratio of 1.16 and a beta of 0.47. The stock has a fifty day moving average price of $742.42 and a 200 day moving average price of $765.94. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 earnings per share. The company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.